For further details see:
ImmunoPrecise's 23-H7 shows promise in pre-clinical COVID-19 studyhome / stock / ipatf / ipatf news
For further details see:
ImmunoPrecise's 23-H7 shows promise in pre-clinical COVID-19 studyMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
ImmunoPrecise Antibodies Ltd. Company Name:
IPATF Stock Symbol:
Market:
ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange Canada NewsWire VICTORIA, BC , Dec. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeu...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year Canada NewsWire Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159 Announced Strategic Partnership ...
ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate VICTORIA, BC , Dec. 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (TSXV: IPA) (IPATD: IPA) (FSE: TQB), a leader in full-service, therapeutic antibody discovery and development and LiteVax...